Vancomycin-induced nephrotoxicity: Mechanism, incidence, risk factors and special populations. A literature review

European Journal of Clinical Pharmacology

Volumn 68, Issue 9, 2012, Pages 1243-1255

  Elyasi, Sepideh ^a   Khalili, Hossein ^a   Dashti Khavidaki, Simin ^a   Mohammadpour, Amirhooshang ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Incidence; Nephrotoxicity; Risk factors; Vancomycin

Indexed keywords

ACETYLGLUCOSAMINIDASE; AMINOGLYCOSIDE; AMPHOTERICIN B; CEPHALOSPORIN; CEPHALOSPORIN DERIVATIVE; CONTRAST MEDIUM; CREATININE; GAMMA GLUTAMYLTRANSFERASE; GENTAMICIN; HYPERTENSIVE FACTOR; LOOP DIURETIC AGENT; MICROSOMAL AMINOPEPTIDASE; NITROGEN; PENICILLIN G; REACTIVE OXYGEN METABOLITE; TACROLIMUS; TOBRAMYCIN; UREA; VANCOMYCIN;

AREA UNDER THE CURVE; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CONTRAST INDUCED NEPHROPATHY; CRITICALLY ILL PATIENT; DISEASE PREDISPOSITION; DISEASE SEVERITY; DOSE CALCULATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG INTERMITTENT THERAPY; DRUG MONITORING; DRUG UPTAKE; HIGH RISK POPULATION; HUMAN; INCIDENCE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NEPHROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PREGNANCY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; STEADY STATE; TREATMENT DURATION;

ADULT; AGE FACTORS; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; KIDNEY; KIDNEY DISEASES; MALE; OXIDATIVE STRESS; PREGNANCY; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; VANCOMYCIN;

EID: 84866628673     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-012-1259-9     Document Type: Review

References (93)

1. Hodoshima N, Masuda S, Inui K (2007) Decreased renal accumulation and toxicity of a new VCM formulation in rats with chronic renal failure. Drug Metab Pharmacokinet 22:419-427
2. Bailie GR, Neal D (1998) Vancomycin ototoxicity and nephrotoxicity, a review. Med Toxicol 3:376-386
3. Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL (2009) Relationship between initial vancomycin concentrationtime profile and nephrotoxicity. Clin Infect Dis 49:507-514
4. Lodise TP, Lomaestro B, Graves J, Drusano GL (2008) Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 52:1330-1336
5. Elting LS, Rubenstein EB, Kurtin D (1998) Mississippi mud in the 1990s:risks and outcomes of vancomycin-associated toxicity in general oncology practice. Cancer 83:2597-2607
6. Newton P (2004) The role of monitoring serum vancomycin levels. Phatol 2:1-2
7. Ingram PR, Lye DC, Tambyah PA, Goh WP, Tam VH, Da F (2008) Risk factors for nephrotoxicity associated with continuous vancomycin infusion in outpatient parenteral antibiotic therapy. Antimicrob Agents Chemother 62:168-171
8. Moellering RC (2006) Vancomycin: a 50-year reassessment. Clin Infect Dis 1 S:3-4
9. Levine DP (2006) Vancomycin: a history. Clin Infect Dis 42S1:5-12
10. Chow AW, Azar RM (1994) Glycopeptides and nephrotoxicity. Intensive Care Med 20S:23-29
11. Arbeit RD, Maki D, Tally FP (2004) Campanaro E, Eisenstein BI. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 38:1673-1681
12. Wilcox MH, Tack KJ, Bouza E (2009) Complicated skin and skin-structure infections and catheter related bloodstream infections: noninferiority of linezolid in a phase 3 study. Clin Infect Dis 48:203-212
13. Pritchard L, Baker C, Leggett J, Sehdev P, Brown A, Bayley KB (2010) Increasing vancomycin serum trough concentrations and incidence of nephrotoxicity. Am J Med 123:1143-1149
14. Huanga LY, Wanga CY, Jangb TN, Yeh HL (2007) Nephrotoxicity of vancomycin and teicoplanin alone and in combination with an aminoglycoside. Taiwan Pharm J 59:1-8
15. Zimmermann AE, Katona BG, Plaisance KI (1995) Association of vancomycin serum concentrations with outcomes in patients with grampositive bacteremia. Pharmacotherapy 15:85-91
16. Toyoguchi T, Takahashi S, Hosoya J, Nakagawa Y, Watanabe H (1997) Nephrotoxicity of vancomycin and drug interaction study with cilastatin in rabbits. Antimicrob Agents Chemother 41:1985-1990
17. Nishino Y, Takemura S, Minamiyama Y, Hirohashi K, Ogino T, Inoue M, Okada S, Kinoshita H (2003) Targeting superoxide dismutase to renal proximal tubule cells attenuates vancomycininduced nephrotoxicity in rats. Free Radic Res 37:272-279
18. Oktema F, Arslan FK, Ozguner F, Candir O, Yilmaz HR, Ciris M et al (2005) In vivo evidences suggesting the role of oxidative stress in pathogenesis of vancomycin-induced nephrotoxicity: protection by erdosteine. Toxicology 215:227-233
19. King DW, Smith MA (2004) Proliferative responses observed following vancomycin treatment in renal proximal tubule epithelial cells. Toxicology 18:797-803
20. Celik I, Cihangiroglu M, Ilhan N, Akpolat N, Akbulut HH (2005) Protective effects of different antioxidants and amrinone on vancomycin-induced nephrotoxicity. basic. Clin Pharmacol Toxicol 97:325-332
21. Cetin H, Olgar S, Oktem F (2007) Novel evidence suggesting an antioxidant property for erythropoietin on vancomycin-induced nephrotoxicity in a rat model. Clin Exp Pharmacol Physiol 34:1181-1185
22. Hodoshima N, Nakano Y, Zumi M (2004) Protective effect of inactive ingredients against nephrotoxicity of vancomycin hydrochloride in rats. Drugs Metab Pharmacokinet 19:68-75
23. Ladino M, Alex M, Schulman IH (2008) Acute and reversible vancomycin nephrotoxicity: a case series. J Nephrol Ren Transplant 3:4-10
24. Nishino Y, Takemura S, Minamiyama Y, Hirohashi K, Tanaka H, Inoue M et al (2002) Inhibition of vancomycin-induced nephrotoxicity by targeting superoxide dismutase to renal proximal tubule cells in the rat. Redox Rep 7:317-319
25. Abraham NG, Asija A, Drummond G, Peterson S (2007) Heme oxygenase-1 gene therapy: recent advances and therapeutic applications. Curr Gene Ther 7:89-108
26. Scandalios JG (2005) Oxidative stress: Molecular perception and transduction of signals triggering antioxidant gene defenses. Braz J Med Biol Res 38:995-1014
27. Hazlewood KA, Brouse SD, Pitcher WD, Hall RG (2010) Vancomycin-associated nephrotoxicity: grave concern or death by character assassination? Am J Med 123:182-193
28. Lee W, Kim RB (2004) Transporters and renal drug elimination. Annu Rev Pharmacol Toxicol 44:137-166
29. Dieterich C, Puey A, Lyn S, Swezey R, Furimsky A, Fairchild D et al (2009) Gene expression analysis reveals new possible mechanisms of vancomycin-induced nephrotoxicity and identifies gene markers candidates. Toxicol Sci 107:258-269
30. Fanos V, Cataldi L (2001) Renal transport of antibiotics and nephrotoxicity: a review. J Chemother 13:461-472
31. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P (2004) Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs: the second international consensus conference of the Acute Dialysis Quality Initiative (ADQI) group. Crit Care 8:R204-R212
32. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG et al (2007) Acute kidney injury network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 11:R31
33. Minejima E, Choi J, Beringer P, Lou M, Tse E, Wong-Beringer A (2011) Applying new diagnostic criteria for acute kidney injury to facilitate early identification of nephrotoxicity in vancomycintreated patients. Antimicrob Agents Chemother 55:3278-3283
34. Shen WC, Chiang YC, Chen HY, Chen TH, Yu FL, Tang CH et al (2011) Nephrotoxicity of vancomycin in patients with methicillinresistant staphylococcus aureus bacteremia. Nephrology 10:1797-1803
35. Waring WS, Moonie A (2011) Earlier recognition of nephrotoxicity using novel biomarkers of acute kidney injury. Clin Toxicol 49:720-728
36. Chawla LS, Kellum JA (2012) Acute kidney injury in 2011: biomarkers are transforming our understanding of AKI. Nat Rev Nephrol 17:68-70
37. Naghibi B, Ghafghazi T, Hajhashemi V, Talebi A (2007) Vancomycin-induced nephrotoxicity in rats: is enzyme elevation a consistent finding in tubular injury? J Nephrol 20:482-488
38. Tanaka A, Aiba T, Otsuka T, Suemaru K, Nishimiya T, Inoue T et al (2010) Population pharmacokinetic analysis of vancomycin using serum cystatin C as a marker of renal function. Antimicrob Agents Chemother 54:778-782
39. Kalil AC (2008) Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: a meta-analysis. In: 48th Interscience Conf Antimicrobial Agents and Chemotherapy (abstract) Washington, DC
40. Vriese A, Vandecasteele SJ, De AS (2010) Recent changes in vancomycin use in renal failure. Kidney Int 77:760-764
41. Bhatt-Mehta V, Schumacher RE, Faix RG, Leady M, Brenner T (1999) Lack of vancomycin-associated nephrotoxicity in newborn infants: a case-control study. Pediatrics 103:48-52
42. Downs NJ (1989) Mild nephrotoxicity associated with vancomycin use. Arch Intern Med 149:1777-1781
43. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A (2006) High-dose vancomycin therapy for methicillin-resistant staphylococcus aureus infections. Arch Intern Med 166:2138-2144
44. Marre R, Schulz E, Anders T, Sack K (1984) Renal tolerance and pharmacokinetics of vancomycin in rats. J Antimicrob Chemother 14:253-260
45. Fauconneau B, De Lemos E, Pariat C, Bouquet S, Courtois P, Piriou A (1992) Chrononephrotoxicity in rat of a vancomycin and gentamicin combination. Pharmacol Toxicol 71:31-36
46. Fauconneau B, Pariat C, Bouquet S, Piriou A, Ingrand P, Courtois P (1993) A comparative study of enzymuria, in the rat, of the drug combinations amikacin/vancomycin and amikacin/teicoplanin. Ren Fail 15:469-473
47. Fauconneau B, Favrelière S, Pariat C, Génévrier A, Courtois P, Piriou A et al (1997) Nephrotoxicity of gentamicin and vancomycin given alone and in combination as determined by enzymuria and cortical antibiotic levels in rats. Ren Fail 19:15-22
48. Wold JS, Turnipseed SA (1981) Toxicicology of vancomycin in laboratory animals. Rev Infect Dis 3:S224-S229
49. Farber BF, Moellering RC Jr (1983) Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981. Antimicrob Agents Chemother 23:138-141
50. Marre R, Schulz E, Hedtke D, Sack K (1985) Influence of fosfomycin and tobramycin on vancomycin-induced nephrotoxicity. Infect 13:190-192
51. Toyoguchi T, Nakagawa Y (1996) Nephrotoxicity and drug interaction of vancomycin. Nippon Yakurigaku Zasshi 107:225-235
52. Sorrell TC, Collignon PJ (1985) A prospective study of adverse reactions associated with vancomycin therapy. J Antimicrob Chemother 16:235-241
53. Malacarne P, Bergamasco S, Donadio C (2006) Nephrotoxicity due to combination antibiotic therapy with vancomycin and aminoglycosides in septic critically ill patients. Chemotherapy 52:178-184
54. Goetz MB, Sayers J (1993) Nephrotoxicity of vancomycin and aminoglycoside therapy separately and in combination. J Antimicrob Chemother 32:325-334
55. Krcméry VJ, Fuchsberger P, Gocár M, Salát T, Bodnárová J, Sobota R et al (1991) Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients. Chemotherapy 37:287-291
56. Vance-Bryan K, Rotschafer JC, Gilliland SS, Rodvold KA, Fitzgerald CM, Guay DR (1994) A comparative assessment of vancomycin-associated nephrotoxicity in the young versus the elderly hospitalized patient. 1994. J Antimicrob Chemother 33:811-821
57. Psevdos GJ, Gonzalez E, Sharp V (2009) Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis. AIDS Read 19:245-248
58. Mellor JA, Kingdom J, Cafferkey M, Keane CT (1985) Vancomycin toxicity: a prospective study. J Antimicrob Chemother 15:773-780
59. Goren MP, Baker DK, Shenep JL (1989) Vancomycin does not enhance amikacin-induced tubular nephrotoxicity in children. Pediatr Infect Dis J 8:278-282
60. Kralovicová K, Spanik S, Halko J, Netriova J, Studena-Mrazova M, Novotny J et al (1997) Do vancomycin serum levels predict failures of vancomycin therapy or nephrotoxicity in cancer patients? J Chemother 9:420-426
61. Cimino MA, Rotstein C, Slaughter RL (1987) Emrich LJ. Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy. Am J Med 83:1091-1097
62. Baddour LM, Wilson WR, Bayer AS (2005) Infective endocarditis: diagnosis, antimicrobial therapy. Circulation 111:394-434
63. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcareassociated. Am J Respir Crit Care Med 2005 171:388-416
64. Rybak M, Lomaestro B, Rotschafer JC (2009) Therapeutic monitoring of vancomycin in adult patients:a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 66:82-98
65. Fagon J, Patrick H, Haas DW (2000) Treatment of Gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial Pneumonia Group. Am J Respir Crit Care Med 161:753-762
66. Rubinstein E, Cammarata S, Oliphant T, Wunderink R (2001) Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multi-center study. Clin Infect Dis 32:402-412
67. Eng RH, Wynn L, Smith SM, Tecson-Tumang F (1989) Effect of intravenous vancomycin on renal function. Chemotherapy 35:320-325
68. Hermsen ED, Hanson M, Sankaranarayanan J, Stoner JA, Florescu MC, Rupp ME (2010) Clinical outcomes and nephrotoxicity associated with vancomycin trough concentrations during treatment of deep-seated infections. Expert Opin Drug Saf 9:9-14
69. Colares VS, Oliveira RB, Abdulkader R (2006) Nephrotoxicity of vancomycin in patients with normal serum creatinine. Nephrol Dial Transplant 21:3608
70. McKamy S, Hernandez E, Jahng M, Moriwaki T, Deveikis A, Le J (2011) Incidence and risk factors influencing the development of vancomycin nephrotoxicity in children. J Pediatr 158:422-426
71. Wan Y (2009) Link between initial vancomycin concentrationtime profile and nephrotoxicity in hospitalised patients. Clin Infect Dis 49:507-514
72. Wong-Beringer A, Joo J, Tse E, Beringer P (2011) Vancomycinassociated nephrotoxicity: a critical appraisal of risk with highdose therapy. Int J Antimicrob Agents 37:95-101
73. Housman ST, Kopcza K, Cross J, Garb J, Skiest D (2010) Incidence and risk factors of vancomycin-induced nephrotoxicity (VIN) in adult, non-intensive care unit patients receiving therapy for 48 hours. 48th Annual Meeting of Infectious Diseases Society of America (IDSA), Vancouver, BC, Canada, 2010. Abstract No 291. Available online at: http://idsa.confex.com/idsa/2010/ webprogram/ Paper4373.html
74. Prabaker KK, Tran TP, Pratummas T, Goetz MB, Graber CJ (2012) Elevated vancomycin trough is not associated with nephrotoxicity among inpatient veterans. J Hosp Med 7:91-97
75. Moffett BS, Kim S, Edwards M (2010) Vancomycin nephrotoxicity may be overstated. J Pediatr 158:865
76. Bosso JA, Nappi J, Rudisill C, Wellein M, Bookstaver PB, Swindler J et al (2011) Relationship between vancomycin trough concentrations and nephrotoxicity: a prospective multicenter trial. Antimicrob Agents Chemother 55s:5475-5479
77. Gasparovic GV (2009) Vancomycin nephrotoxicity in ICU and risk factors for acute renal failure. 22nd European Society of Intensive Care Medicine (ESICM) Annual Congress, Vienna, Austria,
78. Eletronic Poster (No. 1037). Available online at: http:// poster-consultation.esicm.org/ModuleConsultationPoster/poster Detail.aspx?intIdPoster=406
79. Guest JF, Roberts G, Baguley J, Palazzo M (2000) The cost associated with managing nephrotoxicity among vancomycin-treated patients in an intensive care unit. Br J Intens Care 3:78-86
80. Cano EL, Haque NZ, Welch VL, Cely CM, Peyrani P, Scerpella EG et al (2012) Incidence of nephrotoxicity and association with vancomycin use in intensive care unit patients with pneumonia: retrospective analysis of the IMPACT-HAP database. Clin Ther 34:149-157
81. Jelassi ML, Benlmouden A, Lefeuvre S, Mainardi JL, Billaud EM (2011) Level of evidence for therapeutic drug monitoring of vancomycin. Therapie 66:29-37
82. Hutschala D, Kinstner C, Skhirdladze K, Thalhammer F, Muller M, Tschernko E (2009) Influence of vancomycin on renal function in critically ill patients after cardiac surgery. Crit Care Med 111:356-365
83. Jeurissena A, Sluyts I, Rutsaert R (2011) A higher dose of vancomycin in continuous infusion is needed in critically ill patients. Int J Antimicrob Agents 37:75-77
84. Cohen E, Dadashev A, Drucker M, Samra Z, Rubinstein E, Garty M (2002) Once-daily versus twice-daily intravenous administration of vancomycin for infections in hospitalized patients. J Antimicrob Chemother 49:155-160
85. Cataldo MA, Tacconelli E, Grilli E, Pea F, Petrosillo N (2012) Continuous versus intermittent infusion of vancomycin for the treatment of Gram-positive infections: systematic review and meta-analysis. J Antimicrob Chemother 67:17-24
86. Pauly DJ, Musa DM, Lestico MR, Lindstrom MJ, Hetsko CM (1990) Risk of nephrotoxicity with combination vancomycinaminoglycoside antibiotic therapy. Pharmacother 10:378-382
87. Fanos V, Benini D, Vinco S, Pizzini C, Khoory BJ (1997) Glycopeptides and the newborn infant's kidney. Pediatr Med Chir 19:259-262
88. Yi F, Qing H, Jing X, Hua W (2010) Evaluation of nephrotoxicity in 25 elderly patients treated with vancomycin. China Pharmaceutic 7:123-125
89. Nahata MC (1987) Lack of nephrotoxicity in pediatric patients receiving concurrent vancomycin and aminoglycoside therapy. Chemotherapy 33:302-304
90. Fangtang GF (1996) Vancomycin: predictive risk factors for nephrotoxicity and implication for monitoring. Texas Medical Center, Houston
91. Pfeiffer N (2001) Vancomycin may increase risk of nephrotoxicity in neutropenic cancer patients. Oncol Times 23:78
92. Linder N, Edwards R, MeClead R, Mortensen ME, Walson P, Koren G (1993) Safety of vancomycin with or without gentamicin in neonates. Neonatal Network 12:27-30
93. Reyes MP (1989) Vancomycin during pregnancy: does it cause hearing loss or nephrotoxicity in the infant? Am J Obstet Gynecol 161:977-981